BioSpace News Archive

Business

BioScrip Provides Update on Annual Form 10-K Filing Status

BioScrip Inc. announced that it will be filing a Form 12b-25 with the U.S. Securities and Exchange Commission to automatically extend the date for filing its Annual Report on Form 10-K for the year ended December 31, 2017.

March 15, 2018
·
1 min read
FDA

Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome

Tetra Discovery Partners Inc. announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug Application (IND) for BPN14770.

March 15, 2018
·
3 min read
Business

Healogics, Inc. Names Lynn Merritt as New Chief Human Resources Officer

Healogics, Inc. announced that it has appointed Lynn Merritt to serve as Chief Human Resources Officer. Merritt joined Healogics in 2015 as Vice President, Learning and Development.

March 15, 2018
·
2 min read
Biotech Beach

USC President, a US Congressman, a Nobel Laureate, United Neuroscience Executives and pioneering scientists are Amongst 2018 award recipients of Brain Mapping Foundation

The Society for Brain Mapping and Therapeutics (SBMT) officially announced today they will hold their 15th Annual World Congress at the Millennium Biltmore Hotel in DTLA from April 13-15, 2018.

March 15, 2018
·
3 min read
Deals

Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock

The gross offering proceeds to Vanda from the sale of the shares are expected to be approximately $93.5 million.

March 15, 2018
·
3 min read
Business

Ipsidy Announces Results for Year Ended December 31, 2017

Ipsidy Inc. announced its results for the year ended December 31, 2017.

March 15, 2018
·
6 min read
Biotech Beach

Batu Biologics Chief Executive Officer Samuel Wagner to Moderate Congressional Immunotherapy Symposium

Congressional Candidate to Hear Concerns of Industry Leaders in Health Care Innovations

March 15, 2018
·
2 min read
Deals

Is Celgene Considering Going Private?

Celgene has a deep pipeline and a $69 billion market cap, but it could consider going private in 2019 via a leveraged buyout.

March 15, 2018
·
3 min read
·
Mark Terry
Drug Development

FDA Slaps Clinical Hold on Solid Bioscience DMD Gene Therapy Program

A U.S. Food and Drug Administration announced their decision to slap a clinical hold on Solid Biosciences Inc.’s experimental gene therapy treatment for Duchenne muscular dystrophy.

March 15, 2018
·
3 min read
·
Alex Keown
Drug Development

Alexion’s Prospects Rise with Positive Phase III Trial Data

Alexion Pharmaceuticals announced positive results from its pivotal Phase III clinical trial for a life-threatening blood disease.

March 15, 2018
·
2 min read
·
Mark Terry